Yes, all true. But I have to believe there is an explanation for the nons that clarifies all the concerns and speculations. We on the outside just haven't been given it yet.
If there were serious safety concerns, the trial would not have met its safety endpoints, which it did. And the FDA would have stopped the trial, which it didn't. Plus, they certainly wouldn't be continuing the trial with FDA consent.
For me, that's just common sense. Factoring all that in, I think these so-called analysts of course, have their vested interests. But, they know better.
News 
Market Data 
Discover 
AI
